Galectin Antagonist use in Mild Cases of SARS-CoV-2: Pilot Feasibility Randomised, Open Label, Controlled Trial


First clinical trial using a galectin antagonist on SARS-CoV-2.  Prolectin-M lowered viral protein levels to undetectable levels in 3 days (Mann Whitney U=0.000, p<0.029) This represents a novel way to block viral entry and replication.  There were no SAE’s and participants were reactive with IgG within 28 days.